• 1
    Vacanti CA. The history of tissue engineering. J Cell Mol Med. 2006; 10: 56976.
  • 2
    Rubart R, Field LJ. Cardiac regeneration: repopulating the heart. Annu Rev Physiol. 2006; 68: 2949.
  • 3
    Walter DH, Haendeler J, Reinhold J, Rochwalsky U, Seeger F, Honold J, Hoffmann J, Urbich C, Lehmann R, Arenzana-Seisdesdos F, Aicher A, Heeschen C, Fichtlscherer S, Zeiher AM, Dimmeler S. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res. 2005; 97: 114251.
  • 4
    Ye L, Haider HK, Sim EK. Adult stem cells for cardiac repair: choice between skeletal myoblasts and bone marrow stem cells. Exp Biol Med. 2006; 231: 819.
  • 5
    Hristov M, Heussen N, Schober A, Weber C. Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocar-dial infarction: a meta-analysis. J Cell Mol Med. 2006; 10: 72733.
  • 6
    Leobon B, Garcin I, Menaschè P, Vilquin J-T, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci USA. 2003; 100: 780811.
  • 7
    Caplice NM. The future of cell therapy for acute myocardial infarction. Nature. 2006; 3: S12932.
  • 8
    Gnecchi M, He H, Noiseux N, Liang OD, Zhan L, Morello F, Mu H, Melo L, Pratt RE, Inwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006; 20: 6619.
  • 9
    Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, Morine KJ, Gardner TJ, Discher DE, Sweeney HL. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol. 2006; 290: H2196203.
  • 10
    Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vitro. J Clin Invest. 1996; 98: 273945.
  • 11
    Bani D, Bigazzi M. Clinical aspects and therapeutic perspectives of relaxin. Curr Med Chem-Immunol, Endocr Metab Agents. 2005; 5: 40310.
  • 12
    Conrad KP, Novak J. Emering role of relaxin in renal and cardiovascular function. Am J Physiol Integr Comp Physiol. 2004; 287: R25061.
  • 13
    Perna AM, Masini E, Nistri S, Briganti V, Chiappini L, Stefano P, Bigazzi M, Pieroni C, Bani Sacchi T, Bani D. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 2005; 19: 15257.
  • 14
    Wang QD, Sjöquist PO. Myocardial regeneration with stem cells: pharmacological possibilities for efficacy enhancement. Pharmacol Res. 2006; 53: 33140.
  • 15
    Smits PC, Van Geuns RJ, Poldermans D, Bountioukos M, Onderwater EE, Lee CH, Maat AP, Serruys PW. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol. 2003; 42: 20639.
  • 16
    Suzuki K, Murtuza B, Fukushima S, Smolenski RT, Varela-Carver A, Coppen SR, Yacoub MH. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation. 2004; 110: 22530.
  • 17
    Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer. 2006; 118: 6273.
  • 18
    Jegger D, Jeanrenaud X, Nasratullah M, Chassot PG, Mallik A, Tevaearai H, Von Segesser LK, Segers P, Stergiopulos N. Noninvasive Doppler-derived myocardial performance index in rats with myocardial infarction: validation and correlation by conductance catheter. Am J Physiol Heart Circ Physiol. 2006; 290: H15408.
  • 19
    Tei C, Ling LH, Hodge DO. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. J Cardiol. 1995; 26: 35766.
  • 20
    Vandervelde S, Van Luyn MJA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol. 2005; 39: 36376.
  • 21
    Kato M, Dote K, Sasaki S, Goto K, Takemoto H, Habara S, Hasegawa D. Myocardial performance index for assessment of left ventricular outcome in successfully recanalised anterior myocardial infarction. Heart. 2005; 91: 5838.
  • 22
    Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res. 2006; 98: 141421.
  • 23
    Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53: 3147.
  • 24
    Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA. 2001; 98: 103449.
  • 25
    Samuel CS, Du XJ, Bathgate RA, Summers RJ. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther. 2006; 112: 52952.
  • 26
    Hayashidani S, Tsutsui H, Shiomi T, Ikeuki M, Matsusaka H, Suematsu N, Wen J, Eashira K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene tharapy attenuates left ventricular remod-elin and failure after experimental myocardial infarction. Circulation. 2003; 108: 213440.
  • 27
    Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J, Deshpande U, Salles A, Pickford LB, Erikson ME, Hunt TK, Huang X. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 2000; 8: 36170.
  • 28
    Hewitson TD, Mookerjee I, Masterson R, Zhao C, Tregear GW, Becker GJ, Samuel CS. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology. 2007 148: 6609.
  • 29
    Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006; 69: 60413.
  • 30
    Hughes SM, Blau HM. Migration of myoblasts across basal lamina during skeletal muscle development. Nature. 1990; 345: 3503.
  • 31
    Wainwright CL. Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion. Curr Opin Pharmacol. 2004; 4: 1328.
  • 32
    Morita H, Khanal S, Rastogi S, Suzuki G, Imai M, Todor A, Sharov VJ, Goldstein S, Neill TP, Sabbah HN. Selective matrix metalloproinase inhibition attenuates proression of left ventricular dysfunction and remodelling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol. 2006; 290: H25227.
  • 33
    Matsumoto R, Omura T, Yoshiyama M, Hayashi T, Inamoto S, Koh KR, Ohta K, Izumi Y, Nakamura Y, Akioka K, Kitaura Y, Takeuchi K, Yoshikawa J. Vascular endothelial growth factor-expression mesnchymal stem cell transplantation for the treatment of acute myocardial infarction. Atheroscler Thromb Vasc Biol. 2005; 25: 116873.
  • 34
    Wang Y, Haider HK, Ahmad N, Xu M, Ge R, Ashraf M. Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells over-expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol. 2006; 40: 73645.
  • 35
    Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarctium. Ann Thorac Surg. 2005; 80: 22937.